Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

Pharmaceutical Research

Volumn 16, Issue 8, 1999, Pages 1206-1212

  Polli, Joseph W ^a   Jarrett, Jeanne L ^a   Studenberg, Scott D ^a   Humphreys, Joan E ^a   Dennis, Steven W ^a   Brouwer, Kenneth R ^a   Woolley, Joseph L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Blood brain barrier; Caco 2; Cytochrome P450; Ritonavir; Whole body autoradiography

Indexed keywords

AMPRENAVIR; CYTOCHROME P450; GLYCOPROTEIN P; INDINAVIR; RITONAVIR; SAQUINAVIR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CARBAMATES; CATTLE; CENTRAL NERVOUS SYSTEM; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; RITONAVIR; SULFONAMIDES; WHOLE-BODY IRRADIATION;

EID: 0032804327     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018941328702     Document Type: Article

References (29)

1. 1. J. Adkins and D Faulds. Amprenavir. Drugs 55:837-842 (1998).
2. 2. A. Carr-and D. Cooper. HIV Protease Inhibitors. AIDS 10.S151-S157 (1996).
3. 3. J. Lewis. Protease Inhibitors: A therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin. Ther. 19:187-214 (1997).
4. 4. P. Portegies. Review of antiretroviral therapy in the prevention of HIV-related AIDS Dementia Complex (ADC). Drugs 49:25-31 (1995).
5. 5. H. Gendelman, Y. Persidski, A. Ghorpade, J. Limoges, M. Stins, M. Fiala, and R. Morrisett. The neuropathogenesis of the AIDS dementia complex. AIDS 11:S35-S45 (1997).
6. 6. P. Preiss. P-glycoprotein and related transporters. Int. J. Clin. Pharmarcol. Ther. 36.3-8 (1998).
7. 7. S. Letrent, G. Pollack, K. R. Brouwer, and K. L. R Brouwer. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 15:599-605 (1998).
8. 8. G. Luker, V. Rao, C. Crankshaw, J. Dahlheimer, and D. Piwnica-Worms. Characterization of phosphine complexes of technelium (III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry 36:14218-14227 (1997).
9. 9. J. Polli, J. Humphreys, S. Good, S. Studenberg, H. Robertson White, J. Jarrett, and C. Serabjit-Singh. Validation of an in vitro blood brain barrier model: A case study examining the CNS penetration of anti-HIV compounds in vitro and in vivo. Pharm Res. 14:674 (1997).
10. 10. R. Kim, M. Fromm, C. Wandel, B. Leake, A. Wood, D. Roden, and G. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
11. 11. C. Lee, M. Gottesman, C. Cardarelli, M. Ramachandra, K.-T. Jeang, S. Ambudkar, I. Pastan, and S. Dey. HIV-1 protease inhibitors are substrates for the MDR I multidrug transporter. Biochemistry 37:3594-3601 (1998).
12. 12. C. Washington, G. Duran, B. Sikic, and T. Blaschke. Saquinavir is a high affinity substrate for the multidrug transporter, P-glycoprotein. Clin. Pharmacol. Ther. 61:193 (1997).
13. 13. J. Alsenz, H. Steffen, and R Alex. Active apical secretory efflux of HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res. 15:423-428 (1998).
14. 14. L. Gan, S. Yanni, and D. Thakker. Modulation of tight junctions of the Caco-2 cell monolayer by H2-antagonists. Pharm. Res. 15:53-57 (1998).
15. 15. K. Hosoya, K.-J. Kim, and V. Lee. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res. 13:885-890 (1996).
16. 14C]-Amprenavir in Rats. PharmSci Supp. 1:S673 (1998).
17. 17. H. Schinkel, U. Mayer, E. Wagenaar, C. Mol, L. van Deemter, J. Smit, M. van der Valk, A. Voordouw, H. Spits, O. van Tellingre, J. Mark, J. Zijlmans, W. Fibbe, and P. Borst. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94:4028-4033 (1997).
18. 18. F. Hyafil, C. Vergely, P. Du Vignaud, and T. Grand-Perret. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxaminde derivative. Cancer Res. 53:4595-4602 (1993).
19. 19. U. Germann, P. Ford, D. Shlyakhter, V. Mason, and M. Harding. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209, and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein, MRP. Anticancer Drugs 8:141-155 (1997).
20. 20. J. Kempf, K. Marsh, G. Kimar, A. Rodrigues, J. Denissen, E. McDonald, M. Kukulka, A. Hsu, G. Granneman, P. Baroldi, et. al., Leonard. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660 (1997).
21. 14C]-141W94 to rats. ISSX Proceedings 12:108 (1997).
22. 22. D. Livingston, S. Pazhanisamy, D. Porter, and G. Painter. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172:1238-1245 (1995).
23. 23. A. Gooding, A. Hsieh, and J. Woolley. Plasma protein binding and erythrocyte partitioning studies in rats, dogs, and humans with the HIV-1 protease inhibitor, 141W94 (VX-478). ISSX Proceedings 10:347 (1996).
24. 24. A. Mosley, K. Brouwer, and K. R. Brouwer. In Vitro Evaluation of the Serum Binding of an Acridone Carboximide Derivative (GW918), a Potent Inhibitor of P-Glycoprotein. American Association of the Colleges of Pharmacy. Pharm. Res. 13:5-420 (1996).
25. 25. C. Cordon-Cardo, J. O'Brien, D. Casals, L. Rittman-Grauer, J. Biedler, M. Melamed, and J. Bertino. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at the blood-brain barrier site. Proc. Natl. Acad. Sci. USA 86:695-698 (1989).
26. 26. Y. Zhang, X. Guo, E. Lin, and L. Benet. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for novel cysteine protease inhibitors. Drug. Metab. Dispos. 26:360-366 (1998).
27. 27. V. Wacher, C. Wu, and L. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129-134 (1995).
28. 28. L. Jette, E. Beaulieu, J.-M. Leclerc, and R. Beliveau. Cyclosporin A treatment induces overexpression of P-glycoprotein in kidney and other tissues. Am. J. Physiol. 270:F756-F765 (1996).
29. 29. S. Glynn and M. Yazdanian. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. 87:306-310 (1998).